면역 혈액학 시장 : 제품 유형별, 기술별, 검사 유형별, 자동화 레벨별, 용도별 시장 예측(2026-2032년)

The Immunohematology Market is projected to grow by USD 4.27 billion at a CAGR of 8.54% by 2032.

Immunohematology sits at the center of transfusion medicine, transplant support, maternal-fetal care, oncology, emergency medicine, and complex surgery. The field encompasses blood group serology, red cell antibody screening and identification, crossmatching, hemolytic disease testing, donor-recipient compatibility, molecular blood typing, and hemovigilance workflows that protect patients from preventable transfusion reactions.

Demand is supported by durable clinical fundamentals: the WHO reports more than 118 million blood donations are collected globally each year, while aging populations, trauma systems, cancer care, organ transplantation, and chronic disease management continue to increase the need for safe, compatible blood components. As hospitals and reference laboratories face workforce shortages and rising quality expectations, immunohematology is moving from manual serology toward automated, data-connected, and genomics-enabled testing models.

Transformative Shifts in the Landscape

The immunohematology landscape is being reshaped by three converging shifts: automation, molecular precision, and connected quality management. Automated blood bank analyzers and column agglutination or solid-phase platforms are reducing hands-on variability, improving turnaround time, and supporting standardized interpretation across hospital networks and centralized laboratories.

At the same time, molecular immunohematology is expanding beyond specialized reference settings. Red cell genotyping is increasingly used for patients requiring chronic transfusion, including those with sickle cell disease, thalassemia, and oncology-related anemia, where extended antigen matching can reduce alloimmunization risk. Regulatory modernization, electronic crossmatch adoption, and stronger hemovigilance systems are also pushing laboratories to integrate instruments, laboratory information systems, donor databases, and clinical decision-support tools.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is expected to have a cumulative impact across immunohematology by improving pattern recognition, workflow prioritization, inventory forecasting, and decision support. AI-enabled image analysis can assist with agglutination grading, while machine learning models can help flag discrepant results, predict blood utilization, and optimize blood component availability across hospital systems.

The greatest value will come when AI is governed as a validated clinical support layer rather than a replacement for laboratory expertise. Successful adoption requires traceable datasets, bias assessment across diverse blood group distributions, cybersecurity safeguards, and compliance with CLIA, CAP, FDA, EU IVDR, ISO 15189, and local blood safety requirements. Laboratories that combine automation, rules-based algorithms, and human review are positioned to improve consistency without compromising patient safety.

Key Regional Insights

Asia-Pacific is emerging as a high-priority immunohematology region due to expanding hospital infrastructure, rising surgical volumes, national blood service upgrades, and broader adoption of automated blood bank testing in China, India, Japan, South Korea, and Australia. The region also faces a substantial transfusion burden linked to thalassemia, obstetric care, trauma, oncology, and chronic disease management, reinforcing the need for standardized blood grouping, antibody screening, compatibility testing, and hemovigilance. North America remains a mature innovation hub, supported by advanced transfusion services, reference laboratories, robust accreditation, and early adoption of molecular typing, electronic crossmatch workflows, and laboratory information system integration.

Europe benefits from strong national blood systems, EU regulatory harmonization, established quality standards, and high awareness of hemovigilance, with immunohematology laboratories increasingly focused on validated assays, traceability, and data governance under evolving in vitro diagnostic requirements. Latin America is improving access through centralized blood banks, national blood safety initiatives, and public-private investments in Brazil and Mexico, while uneven infrastructure continues to create demand for scalable automation and standardized testing. The Middle East is strengthening transfusion capacity through GCC healthcare modernization, tertiary hospital expansion, transplant services, oncology care, and medical tourism. Africa continues to prioritize blood availability, infectious disease screening, maternal health, pediatric transfusion safety, and emergency care, creating demand for cost-efficient immunohematology solutions suited to decentralized and resource-constrained settings.

Key Group Insights

ASEAN markets are advancing through hospital network expansion, public blood service modernization, medical tourism, and regional demand for reliable pretransfusion testing across diverse healthcare systems. The group's high population base and growing access to surgery, oncology, and maternal care are increasing the importance of standardized blood grouping, antibody screening, and quality assurance. The GCC is investing in high-acuity care, transplant programs, oncology centers, digital health infrastructure, and nationally coordinated healthcare modernization, which supports adoption of automated immunohematology platforms, laboratory connectivity, and quality management systems.

The European Union is shaped by IVDR implementation, cross-border quality expectations, national hemovigilance programs, and established transfusion guidelines, creating demand for validated assays, traceable data, and compliant laboratory workflows. BRICS countries represent a large-volume opportunity driven by population scale, healthcare access expansion, blood service modernization, and domestic manufacturing ambitions across diagnostics and healthcare technologies. G7 markets remain the benchmark for premium automation, molecular immunohematology, regulatory rigor, and advanced reference testing, while NATO countries emphasize resilient blood supply chains, interoperability, emergency preparedness, and continuity of transfusion services for civilian and defense medical systems.

Key Country Insights

The United States leads in advanced transfusion medicine, red cell genotyping, reference testing, electronic crossmatch adoption, and FDA-regulated blood safety practices, while Canada emphasizes nationally coordinated blood services and high-quality hospital transfusion programs. Mexico is strengthening centralized testing capacity and improving blood safety standardization across public and private healthcare settings. Brazil is expanding transfusion infrastructure and remains Latin America's largest healthcare system, with demand supported by complex surgery, oncology care, trauma services, and chronic disease management.

In Europe, the United Kingdom maintains a highly structured transfusion environment supported by national blood services, hemovigilance, and specialized reference testing. Germany and France are notable for sophisticated transfusion networks, strong diagnostics capabilities, and life sciences expertise, while Italy and Spain maintain mature hospital-based transfusion services supported by established quality systems. Russia has broad hospital demand and transfusion needs across a large geography, although procurement, sanctions-related constraints, and technology-access limitations can affect modernization. In Asia-Pacific, China is scaling blood service modernization and laboratory automation across major urban centers, India is addressing access and standardization across a large and diverse patient base, Japan and South Korea emphasize advanced automation, quality assurance, and aging-population care, and Australia maintains a highly regulated, consolidated transfusion environment with strong national oversight and traceability.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize platforms that combine automation, assay reliability, interoperability, and regulatory readiness. Vendors and laboratories can differentiate by integrating immunohematology analyzers with laboratory information systems, enabling electronic crossmatch workflows, supporting remote quality review, and offering scalable solutions for both centralized blood centers and hospital transfusion services.

Strategic investment should focus on molecular blood group typing, AI-assisted interpretation, cybersecurity, staff training, and evidence generation that demonstrates reduced turnaround time, fewer manual errors, stronger traceability, and improved patient outcomes. Partnerships with blood services, hospital networks, reference laboratories, and public health agencies will be critical for expanding access while maintaining compliance, workflow efficiency, and clinical confidence.

Research Methodology

This executive summary is developed using a structured methodology that combines secondary research, expert validation, and data triangulation. Sources include public health agencies, blood safety organizations, regulatory bodies, peer-reviewed transfusion medicine literature, product documentation, accreditation standards, and clinical practice guidelines.

The analysis evaluates demand drivers, technology adoption, regulatory shifts, regional healthcare infrastructure, and end-user requirements across hospitals, blood banks, reference laboratories, and academic medical centers. Insights are validated by comparing multiple authoritative sources and by assessing consistency with observable industry behavior, including automation adoption, molecular testing expansion, hemovigilance priorities, regulatory compliance, and digital laboratory transformation.

Conclusion

Immunohematology is entering a more automated, data-rich, and precision-driven phase as healthcare systems seek safer transfusion practices, faster compatibility testing, and stronger blood supply resilience. The convergence of serology, molecular diagnostics, AI-enabled decision support, and integrated laboratory information systems is redefining how blood banks manage complexity and risk.

Organizations that invest in validated automation, regulatory compliance, workforce enablement, and interoperable data infrastructure will be best positioned to strengthen clinical performance. The outlook remains anchored in essential clinical need: every transfusion decision depends on accurate immunohematology testing, making innovation in this field central to patient safety and modern healthcare delivery.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Immunohematology Market, by Product Type

• 7.1. Analyzers & Systems
  • 7.1.1. Fully-Automated
  • 7.1.2. Semi-Automated
• 7.2. Reagents & Kits

8. Immunohematology Market, by Technology

• 8.1. Gel Card Technology
• 8.2. Solid Phase Technology
• 8.3. Tube Testing

9. Immunohematology Market, by Test Type

• 9.1. Blood Typing
• 9.2. Antibody Screening & Identification
• 9.3. Crossmatching
• 9.4. Antiglobulin Testing
• 9.5. Donor Screening Tests

10. Immunohematology Market, by Automation Level

• 10.1. Manual
• 10.2. Semi-Automated
• 10.3. Fully Automated

11. Immunohematology Market, by Application

• 11.1. Antibody Screening
• 11.2. Blood Transfusion
• 11.3. Disease Diagnosis
• 11.4. Pregnancy

12. Immunohematology Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Immunohematology Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Immunohematology Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Atlas Medical GmbH
• 16.3. Beckman Coulter, Inc.
• 16.4. Bio-Rad Laboratories, Inc.
• 16.5. bioMerieux SA
• 16.6. Diagast SAS
• 16.7. DiaSorin S.p.A.
• 16.8. F. Hoffmann-La Roche Ltd.
• 16.9. Grifols, S.A.
• 16.10. Immucor, Inc.
• 16.11. J. Mitra & Co. Pvt. Ltd.
• 16.12. Merck KGaA
• 16.13. Nova Biomedical Corporation
• 16.14. Ortho Clinical Diagnostics
• 16.15. QuidelOrtho Corporation
• 16.16. Quotient Limited
• 16.17. Sanquin Reagents B.V.
• 16.18. Siemens Healthineers AG
• 16.19. Span Diagnostics Ltd.
• 16.20. Sysmex Corporation
• 16.21. Thermo Fisher Scientific Inc.
• 16.22. Trinity Biotech plc
• 16.23. Tulip Diagnostics (P) Ltd.